1-Methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Δψm) in rat striatum

Experimental Neurology

Volumn 179, Issue 1, 2003, Pages 103-110

  Nakai, Masami ^a   Mori, Atsushi ^a   Watanabe, Akihito ^a   Mitsumoto, Yasuhide ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Alamar blue; JC 1; Mitochondrial dysfunction; MPP+; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DOPAMINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; TYROSINE 3 MONOOXYGENASE; VANOXERINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; FLUOROMETRY; IMMUNOREACTIVITY; MALE; MITOCHONDRIAL RESPIRATION; NERVE DEGENERATION; NERVE ENDING; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT;

EID: 0037228983     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.8056     Document Type: Article

References (42)

1. Ali, S. F., S. N. David, G. D. Newport, J. L. Cadet, and W. Slikker, Jr. 1994. MPTP-induced oxidative stress and neurotoxicity are age-dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 18: 27-34.
2. Azbill, R. D., X. Mu, A. J. Bruce-Keller, M. P. Mattson, and J. E. Springer. 1997. Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury. Brain Res. 765: 283-290.
3. Beal, M. F., R. T. Matthews, A. Tieleman, and C. W. Shults. 1998. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 783: 109-114.
4. Chan, P., L. E. DeLanney, I. Irwin, J. W. Langston, and D. Di Monte. 1991. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57: 348-351.
5. Chan, P., J. W. Langston, I. Irwin, L. E. DeLanney, and D. A. Di Monte. 1993. 2-Deoxyglucose enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse brain. J. Neurochem. 61: 610-616.
6. Di Monte, D., S. A. Jewell, G. Ekstrom, M. S. Sandy, and M. T. Smith. 1986. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP3) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun. 137: 310-315.
7. Fallon, J., R. T. Matthews, B. T. Hyman, and M. F. Beal. 1997. MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress. Exp. Neurol. 144: 193-198.
8. Fredriksson, A., P. Eriksson, and T. Archer. 1997. MPTP-induced deficits in motor activity: Neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN). J. Neural Transm. 104: 579-592.
9. Gerlach, M., and P. Riederer. 1996. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103: 987-1041.
10. Gonzalez, R. J., and J. B. Tarloff. 2001. Evaluation of hepatic subcellular fractions for Alamar blue and MTT reductase activity. Toxicol. In Vitro 15: 257-259.
11. Hattori, N., M. Tanaka, T. Ozawa, and Y. Mizuno. 1991. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30: 563-571.
12. Heikkila, R. E., L. Manzino, F. S. Cabbat, and R. C. Duvoisin. 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469.
13. Heikkila, R. E., W. J. Nicklas, and R. C. Duvoisin. 1985. Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP3) to rats. Neurosci. Lett. 59: 135-140.
14. Javitch, J. A., R. J. D'Amato, S. M. Strittmatter, and S. H. Snyder. 1985. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82: 2173-2177.
15. Klivenyi, P., D. St Clair, M. Wermer, H. C. Yen, T. Oberley, L. Yang, and M. Flint Beal. 1998. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiol. Dis. 5: 253-258.
16. Langston, J. W., P. Ballard, J. W. Tetrud, and I. Irwin. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
17. Marsden, C. D. 1994. Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 57: 672-681.
18. Matthews, R. T., R. J. Ferrante, P. Klivenyi, L. Yang, A. M. Klein, G. Mueller, R. Kaddurah-Daouk, and M. F. Beal. 1999. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157: 142-149.
19. Miller, G. W., J. K. Staley, C. J. Heilman, J. T. Perez, D. C. Mash, D. B. Rye, and A. I. Levey. 1997. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann. Neurol. 41: 530-539.
20. Mitsumoto, Y., A. Watanabe, A. Mori, and N. Koga. 1998. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 248: 660-663.
21. Mizuno, Y., S. Matuda, H. Yoshino, H. Mori, N. Hattori, and S. Ikebe. 1994. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35: 204-210.
22. Mizuno, Y., S. Ohta, M. Tanaka, S. Takamiya, K. Suzuki, T. Sato, H. Oya, T. Ozawa, and Y. Kagawa. 1989. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163: 1450-1455.
23. Mizuno, Y., T. Saitoh, and N. Sone. 1987. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem. Biophys. Res. Commun. 143: 971-976.
24. Mizuno, Y., H. Yoshino, S. Ikebe, N. Hattori, T. Kobayashi, S. Shimoda-Matsubayashi, H. Matsumine, and T. Kondo. 1998. Mitochondrial dysfunction in Parkinson's disease. Ann. Neurol. 44: S99-S109.
25. Murphy, A. N., G. Fiskum, and M. F. Beal. 1999. Mitochondria in neurodegeneration: Bioenergetic function in cell life and death. J. Cereb. Blood Flow Metab. 19: 231-245.
26. Nakai, M., Z. H. Qin, J. F. Chen, Y. Wang, and T. N. Chase. 2000. Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation. J. Neurochem. 74: 647-658.
27. Nicklas, W. J., I. Vyas, and R. E. Heikkila. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36: 2503-2508.
28. Przedborski, S., V. Kostic, V. Jackson-Lewis, A. B. Naini, S. Simonetti, S. Fahn, E. Carlson, C. J. Epstein, and J. L. Cadet. 1992. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12: 1658-1667.
29. Ramsay, R. R., and T. P. Singer. 1986. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261: 7585-7587.
30. Schapira, A. H., J. M. Cooper, D. Dexter, J. B. Clark, P. Jenner, and C. D. Marsden. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54: 823-827.
31. Schapira, A. H., J. M. Cooper, D. Dexter, P. Jenner, J. B. Clark, and C. D. Marsden. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269.
32. Schapira, A. H., M. Gu, J. W. Taanman, S. J. Tabrizi, T. Seaton, M. Cleeter, and J. M. Cooper. 1998. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44: S89-98.
33. Schulz, J. B., D. R. Henshaw, R. T. Matthews, and M. F. Beal. 1995. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. 132: 279-283.
34. Schulz, J. B., D. R. Henshaw, D. Siwek, B. G. Jenkins, R. J. Ferrante, P. B. Cipolloni, N. W. Kowall, B. R. Rosen, and M. F. Beal. 1995. Involvement of free radicals in excitotoxicity in vivo. J. Neurochem. 64: 2239-2247.
35. Singh, Y., R. Bhatnagar, G. S. Sidhu, J. K. Batra, and G. Krishna. 1989. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine inhibits proton motive force in energized liver mitochondria. Arch. Biochem. Biophys. 271: 217-222.
36. Springer, J. E., R. D. Azbill, and S. L. Carlson. 1998. A rapid and sensitive assay for measuring mitochondrial metabolic activity in isolated neural tissue. Brain Res. Brain Res. Protoc. 2: 259-263.
37. Storey, E., B. T. Hyman, B. Jenkins, E. Brouillet, J. M. Miller, B. R. Rosen, and M. F. Beal. 1992. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 58: 1975-1978.
38. Sullivan, P. G., M. B. Thompson, and S. W. Scheff. 1999. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp. Neurol. 160: 226-234.
39. Tatton, W. G., and R. M. Chalmers-Redman. 1998. Mitochondria in neurodegenerative apoptosis: An opportunity for therapy? Ann. Neurol. 44: S134-S141.
40. Tatton, W. G., and C. W. Olanow. 1999. Apoptosis in neurodegenerative diseases: The role of mitochondria. Biochim. Biophys. Acta 1410: 195-213.
41. Tipton, K. F., and T. P. Singer. 1993. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61: 1191-1206.
42. Wu, E. Y., M. T. Smith, G. Bellomo, and D. Di Monte. 1990. Relationships between the mitochondrial transmembrane potential. ATP concentration, and cytotoxicity in isolated rat hepatocytes. Arch. Biochem. Biophys. 282: 358-362.